Dianabol vs GHRP-2
Well Studied vs Well Studied
monitor Mechanism-based · 47% Both Dianabol and GHRP-2 affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Dianabol GHRP-2
Weight 300.44 Da 817.9 Da
Half-life ~4-6 hours ~30 minutes
Chain — 6 amino acids
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Synthetic hexapeptide
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
GHRP-2
01 Potent stimulation of natural growth hormone release
02 Enhanced muscle growth and recovery
03 Improved body composition and fat metabolism
04 Better sleep quality and recovery
05 Increased appetite (can be beneficial for bulking)
06 Maintains natural GH pulsatile release patterns
07 Synergistic effects when combined with GHRH peptides
Dosing Protocols
Dianabol
20-50 mg/day / Split doses throughout the day
GHRP-2
100-300 mcg / 2-3x daily
GH optimization 100-150 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Pre-sleep protocol 100-200 mcg Before bed
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
GHRP-2
Increased appetite (less than GHRP-6)
Mild water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetic retinopathy
WADA prohibited for competitive athletes
Research Evidence
Dianabol GHRP-2
Status Well Studied Well Studied
References 5 studies 3 studies
Latest 2017 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.